Copyright © 1995 by the European Society of Cardiology.
© 1995 The European Society of Cardiology
Comparative study on the effects of intracoronary nicorandil and nitroglycerin in ischaemic, reperfused porcine hearts
*Department of Cardiology, University of Marburg Germany
Department of Medical Biometry, University of Marburg Germany
Department of Experimental Animal Research, University of Göttingen Germany
revised 30 August 1994; accepted 25 October 1994.
Correspondence: Prof. Dr H. H. Klein. Abteilung für Kardiologie, Städt. Krankenanstalten Idar-Oberstein GmbH. Dr. Ottmar-Kohler-Str 2, 55743 ldar-Oberstein, Germany.
Abstract
The direct cardioprotective properties of nitroglycerin and nicorandil were compared in regionally ischaemic (45 min), reperfused (24 h) porcine hearts. Intracoronary treatments, which were started 15 min prior to occlusion of the distal left anterior descending coronary artery (LAD), were continuously administered for 105min. The following equi-hypotensive drug dosages were used in nine pigs each; nitroglycerin 6 fig. kg–1 x min before ischaemia and during 45 min of reperfusion, 0.6 µg. kg–1x min during ischaemia; nicorandil 5 fig. kg–1 x min before ischaemia and during 45 min of reperfusion, and 0.5 fig. kg–1 x min during ischaemia. Nine control animals were treated with isotonic sodium hydrochloride solution (1 ml. min–1).
Despite comparable effects on blood pressure, intracoronary nicorandil, in contrast to intracoronary nitroglycerin, did not increase heart rate. Although neither drug affected coronary blood flow significantly, nicorandil substantially reduced regional myocardial oxygen consumption before coronary artery occlusion ( – 37±22%, P=0003 vs control group, P=0.01 vs nitroglycerin treatment). Infarct sizes (tetrazolium method) after 45 min of ischaemia and 24 h of reperfusion were significantly decreased by nicorandil (control group 76.9 ± 19%, nicorandil group 49.3 ± 24%, P=0.012)whereas nitroglycerin exhibited a borderline effect (62.5 ± 15%, P=0.054). Both treatments resulted in improved regional systolic shortening of the reperfused segment at the end of the experiments but this was not significant. At these drug dosages the direct cardioprotective action of nicorandil is slightly superior to nitroglycerin. This may be ascribed to its K-channel opening property associated with reduced regional myocardial oxygen consumption before the onset of ischaemia.
Key Words: Nitroglycerin • nicorandil • infarct size • coronary blood flow • regional myocardial infarction • pigs
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  X. Liu, Y. Huang, P. Pokreisz, P. Vermeersch, G. Marsboom, M. Swinnen, E. Verbeken, J. Santos, M. Pellens, H. Gillijns, et al. Nitric Oxide Inhalation Improves Microvascular Flow and Decreases Infarction Size After Myocardial Ischemia and Reperfusion J. Am. Coll. Cardiol., August 21, 2007; 50(8): 808 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Ikeda, T Yasu, N Kubo, S Hashimoto, Y Tsuruya, M Fujii, M Kawakami, and M Saito Nicorandil versus isosorbide dinitrate as adjunctive treatment to direct balloon angioplasty in acute myocardial infarction Heart, February 1, 2004; 90(2): 181 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Shinmura, X.-L. Tang, H. Takano, M. Hill, and R. Bolli Nitric oxide donors attenuate myocardial stunning in conscious rabbits Am J Physiol Heart Circ Physiol, December 1, 1999; 277(6): H2495 - H2503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ito, Y. Taniyama, K. Iwakura, N. Nishikawa, T. Masuyama, T. Kuzuya, M. Hori, Y. Higashino, K. Fujii, and T. Minamino Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction J. Am. Coll. Cardiol., March 1, 1999; 33(3): 654 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.J. Patel, H.J. Purcell, and K.M. Fox Cardioprotection by opening of the KATPchannel in unstable angina: Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil Eur. Heart J., January 1, 1999; 20(1): 51 - 57. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Yamashita, R. A. Schmid, S. Fujino, J. D. Cooper, and G. A. Patterson NICORANDIL, A POTENT ADENOSINE TRIPHOSPHATE-SENSITIVE POTASSIUM-CHANNEL OPENER, AMELIORATES LUNG ALLOGRAFT REPERFUSION INJURY J. Thorac. Cardiovasc. Surg., November 1, 1996; 112(5): 1307 - 1314. [Abstract] [Full Text]
|
|